Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory knowledge and scientific expertise in this therapeutic area. Partnering with a single integrated CRO/CDMO can also save sponsors up to 40% in both time and costs.
In this issue of The Altascientist, learn about key considerations in each phase of ophthalmic drug development―from prototype formulation through preclinical testing, to early phase clinical trials, and manufacturing (three case studies included).
Download your copy today!
